DRUG SURVIVAL RATES AND COST OF BIOLOGICAL AGENTS FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN THE BALEARIC ISLANDS (SPAIN)
Author(s)
Ventayol P
Hospital Son Espases, Palma de Mallorca, Spain
Presentation Documents
OBJECTIVES There are few studies combining dose regimen in routine clinical practice, drug survival rates and costs of biological agents for the treatment of naïve patients with moderate-to-severe psoriasis in the clinical practice. To assess the dose regimen in routine clinical practice, drug survival rate (persistence rate) and efficiency (cost per persistence) for etanercept (ETN), adalimumab (ADA) and ustekinumab (UST) in a real practice clinical setting. METHODS A retrospective study on psoriasis patients aged ≥18 years, naïve to a biological agent and a minimum of 6 months of treatment was performed in 5 public health system hospitals in the Balearic Islands (Spain) for the period from January 1st
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PSS37
Topic
Patient-Centered Research
Topic Subcategory
Adherence, Persistence, & Compliance
Disease
Sensory System Disorders